A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

被引：0
作者：
Akira Tsuburaya
Satoshi Morita
Yasuhiro Kodera
Michiya Kobayashi
Kohei Shitara
Kensei Yamaguchi
Takaki Yoshikawa
Kazuhiro Yoshida
Shigefumi Yoshino
Jun-ichi Sakamoto
机构：
[1] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[2] Yokohama City University Medical Center,Department of Biostatistics and Epidemiology
[3] Nagoya University Graduate School of Medicine,Department of Surgery II
[4] Kochi Medical School,Department of Surgery
[5] Aichi Cancer Center Hospital,Department of Clinical Oncology
[6] Saitama Cancer Center,Department of Gastroenterology
[7] Gifu Graduate School of Medicine,Department of Surgical Oncology
[8] Yamaguchi University Graduate School of Medicine,Department of Digestive Surgery and Surgical Oncology
[9] Nagoya University Graduate School of Medicine,Epidemiological and Clinical Research Information Network
来源：
BMC Cancer | / 12卷
关键词：
Biomarker; Capecitabine; Cisplatin; Clinical trial; Gastric cancer; S-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 148 条
[31]  
Kobayashi O(undefined)undefined undefined undefined undefined-undefined
[32]  
Takiyama W(undefined)undefined undefined undefined undefined-undefined
[33]  
Toh Y(undefined)undefined undefined undefined undefined-undefined
[34]  
Nagaie T(undefined)undefined undefined undefined undefined-undefined
[35]  
Takagi S(undefined)undefined undefined undefined undefined-undefined
[36]  
Yamamura Y(undefined)undefined undefined undefined undefined-undefined
[37]  
Yanaoka K(undefined)undefined undefined undefined undefined-undefined
[38]  
Orita H(undefined)undefined undefined undefined undefined-undefined
[39]  
Takeuchi M(undefined)undefined undefined undefined undefined-undefined
[40]  
Kang YK(undefined)undefined undefined undefined undefined-undefined
12345678910